Stephen C. Blacklow, M.D., Ph.D.
Dr. Stephen Blacklow currently serves as an MPM BioImpact Advisor. Stephen is the Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and a member of the Department of Cancer Biology at the Dana-Farber Cancer Institute.
Research by Stephen’s team has furthered the understanding of how cells can communicate with one another and cause each other to undergo downstream changes, which is an important mechanism in many cancers. His research on the Notch pathway has led to the development of new investigational therapies for hematologic malignancies such as T cell ALL.
Of his many other awards and professional affiliations, Stephen received the National Cancer Institute’s prestigious Outstanding Investigator Award in 2017 and was elected to the Association of American Physicians in 2018. Stephen also directed the MD-PhD Program in Basic and Translational Sciences at Harvard Medical School and has served on Advisory Committees for pre-clinical departments, graduate programs, and MD-PhD programs at several major research universities and institutions, including Stanford, the University of Pennsylvania, and the Memorial Sloan Kettering Cancer Center.
Stephen earned his M.D. and Ph.D. from Harvard University in 1991. He completed his residency in Clinical Pathology at Brigham and Women’s Hospital and conducted his postdoctoral research at the Whitehead Institute with Dr. Peter S. Kim.